Its roughly 30% average weight loss could expand options and accelerate a tiered treatment market ranging from oral pill convenience to surgical intervention for those with severe obesity.
Novo beat Q1 expectations thanks to Wegovy pill buzz as Lilly readies rival Foundayo, setting up weight loss drugs’ next ad showdown.
Powerful data and analysis on nearly every digital topic.
Become a ClientWant more marketing insights?
Sign up for EMARKETER Daily, our free newsletter.
Thanks for signing up for our newsletter!
You can read recent articles from EMARKETER here.